Androgen Deprivation

Active Surveillance of Prostate Cancer Increasing in the U.S.

Active Surveillance of Prostate Cancer Increasing in the U.S.

Many men with low-risk disease being spared prostatectomy, radiation, and androgen deprivation treatment.

Prostate Cancer Treatment May Increase Colorectal Cancer Risk

Prostate Cancer Treatment May Increase Colorectal Cancer Risk

By

Researchers observed greater incidences of colorectal cancer among patients who underwent bilateral orchiectomy, surgery, and ADT.

Androgen Deprivation Therapy Increases Metabolic Syndrome

Androgen Deprivation Therapy Increases Metabolic Syndrome

Researchers observed increases in components of metabolic syndrome and in the prevalence of full metabolic syndrome among men with prostate cancer treated with ADT.

Androgen Deprivation Therapy Increases Diabetes Risk

Androgen Deprivation Therapy Increases Diabetes Risk

Findings among men treated for localized prostate cancer.

Short-Term Androgen Deprivation Plus Radiation Superior

Short-Term Androgen Deprivation Plus Radiation Superior

By

The combination improved oncologic control better than dose-escalated radiotherapy alone in men with intermediate-risk prostate cancer.

ADT Therapy for Prostate Cancer Linked to Impaired Thinking

ADT Therapy for Prostate Cancer Linked to Impaired Thinking

Men with a particular gene mutation affected most, researchers find.

Early ADT for Recurrent Prostate Cancer May Hike Death Risk

Early ADT for Recurrent Prostate Cancer May Hike Death Risk

By

This effect appears to occur mainly in men who experience recurrence when they are younger than 65 and in those with low-risk cancer.

Statins May Help Prostate Cancer Patients on ADT

Statins May Help Prostate Cancer Patients on ADT

Prostate cancer remained stable for an average 10 extra months in men taking statins, but more trials are needed to confirm benefits, researchers say.

Monitor Older Men on ADT for Diabetes and CVD

Monitor Older Men on ADT for Diabetes and CVD

Prolonged androgen deprivation treatment ups risk in older men with prostate cancer, especially those with comorbidities.

Time to PCa Metastasis Affects Overall Survival

Time to PCa Metastasis Affects Overall Survival

By

Median time to death was shortest in men with metastatic disease at diagnosis.

Androgen Deprivation Therapy Impairs Physical Function

Androgen Deprivation Therapy Impairs Physical Function

Physical side effects seen over first 12 months of androgen deprivation therapy (ADT) persisted or worsened over 3 years of follow-up.

Statins Promising for Cancers

Statins Promising for Cancers

By

Studies suggest that these cholesterol-lowering drugs can improve treatment of genitourinary cancers and prevent contrast-induced nephropathy.

Low Testosterone After ADT Linked with Improved Survival

Low Testosterone After ADT Linked with Improved Survival

By

Low serum testosterone levels within the first year of androgen-deprivation therapy (ADT) is associated with improved cause-specific survival.

Factors Affecting Treatment Regret in Prostate Cancer

Factors Affecting Treatment Regret in Prostate Cancer

The researchers found that 12% of the participants experienced treatment decisional regret.

CVD Risk Increased in Patients on Androgen Deprivation Therapy for Prostate Cancer

CVD Risk Increased in Patients on Androgen Deprivation Therapy for Prostate Cancer

Highest risk during first 6 months of ADT among men who had cardiovascular events before treatment.

Short-Term ADT+Radiotherapy Does Not Help Intermediate PCa Survival

Short-Term ADT+Radiotherapy Does Not Help Intermediate PCa Survival

Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.

Statins Plus ADT After Prostate Cancer Radiotherapy Ups Survival

Statins Plus ADT After Prostate Cancer Radiotherapy Ups Survival

By

Researchers observed a significant 36% decreased overall and prostate cancer-specific mortality.

Radiation Plus ADT Beneficial in Node-Positive Prostate Cancer

Radiation Plus ADT Beneficial in Node-Positive Prostate Cancer

By

The 5-year risk of overall mortality is decreased by 50% compared with androgen deprivation therapy alone.

Adding Statins to ADT May Delay PCa Progression

Adding Statins to ADT May Delay PCa Progression

By

Prostate cancer progression was delayed by a median 10 months in statin users.

Bipolar Androgen Therapy Helps Hormone Therapy-resistant PCa

Bipolar Androgen Therapy Helps Hormone Therapy-resistant PCa

Small study suggests alternating testosterone levels may make hormonal therapy work longer for prostate cancer patients.

ADT-RT Combo Offers Better Outcomes

ADT-RT Combo Offers Better Outcomes

By

Longer cancer-specific and overall survival seen in older men with locally advanced or high-risk PCa

PSA Doubling Time Predicts Salvage Radiation Outcomes

PSA Doubling Time Predicts Salvage Radiation Outcomes

By

PSA doubling time of 6 months or less and seminal vesicle invasion were significant predictors of biochemical recurrence.

Prolonged Prostate Cancer Hormone Therapy Raises Fracture Risk

Prolonged Prostate Cancer Hormone Therapy Raises Fracture Risk

By

Androgen-deprivation therapy (ADT) for more than 1 year is associated with a 2.5 times higher odds of fracture in prostate cancer patients.

Testosterone Replacement Therapy (TRT) Beneficial in Diabetes Mellitus Patients

Testosterone Replacement Therapy (TRT) Beneficial in Diabetes Mellitus Patients

Testosterone replacement therapy (TRT) may lower hemoglobin levels and improve lipid profile in diabetic men with androgen deficiency.

Androgen Deprivation Therapy (ADT) Raises Heart-Related Death Risk

Androgen Deprivation Therapy (ADT) Raises Heart-Related Death Risk

But overall risk of heart-related death risk from prostate cancer treatment is small, researchers say.

Chemo-ADT Combo Ups Survival in Patients with Metastatic PCa

Chemo-ADT Combo Ups Survival in Patients with Metastatic PCa

By

Starting docetaxel with androgen deprivation therapy prolonged median overall survival by more than 13 months versus ADT alone.

ADT May Be Safely Deferred After PSA Relapse

ADT May Be Safely Deferred After PSA Relapse

By

Immediate ADT found to offer little or no survival advantage to prostate cancer who experience biochemical recurrence.

Adding ADT to Radiotherapy Improves Prostate Cancer Outcomes

Adding ADT to Radiotherapy Improves Prostate Cancer Outcomes

By

The combined treatment was associated with a reduced risk of biochemical and clinical progression compared with radiotherapy alone.

Osteoporosis May Be Present Before Prostate Cancer ADT

Osteoporosis May Be Present Before Prostate Cancer ADT

By

Danish study reveals a 10% prevalence of osteoporosis among men due to start androgen-deprivation therapy.

PSA Nadir in ADT Recipients: The Lower, The Better

PSA Nadir in ADT Recipients: The Lower, The Better

By

The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.

Sign Up for Free e-newsletters